Oncology Revenue Infrastructure
Medbilling RCM provides HIPAA-compliant oncology billing services covering chemotherapy J-code accuracy, drug wastage billing (modifier JW), buy-and-bill reimbursement at ASP+6%, infusion administration CPT coding (96413–96417), prior authorization management, and radiation oncology billing — ensuring accurate claims and maximum reimbursements for oncology practices and cancer centers.
Infusion Sequencing Expertise
Chemotherapy infusion coding is sequence-dependent and time-based. The order drugs are administered, how long each infusion runs, and whether infusions are concurrent or sequential determines which CPT codes are billed. A single coding error affects the entire encounter.
First chemotherapy drug — initial infusion CPT, regardless of drug cost or volume
Each additional hour of the same initial drug — billed per hour after the first
Second chemotherapy drug administered after the first — sequential, not concurrent
Chemotherapy administered by direct IV push — 15 minutes or less, single code
Each additional push injection of a different chemotherapy drug at the same encounter
Single-use vials often contain more drug than the dose administered. The unused portion (wastage) is separately billable using modifier JW on the J-code line — where payer rules allow. Missed JW billing represents thousands in annual revenue loss for busy oncology practices. We capture JW on every eligible claim.
Request J-Code AuditOncology Billing Challenges
Oncology billing involves buy-and-bill drug procurement, chemotherapy sequencing rules, J-code precision on drugs worth thousands per dose, HIPAA-protected patient data, and NCCN compendia requirements for off-label prior authorization.
Every chemotherapy claim requires the exact HCPCS J-code matched to drug name, dose, and administration route. J-code errors on oncology drugs worth $10,000–$150,000 per dose create immediate cash flow crises. We verify every J-code against drug administration records, calculate units from administered dose, and track ASP+6% reimbursement rates for Medicare buy-and-bill.
Chemotherapy infusion coding is sequence-dependent. Initial infusion (96413), additional hours (96415), sequential drug (96417), and concurrent infusion coding each have distinct rules. Incorrect sequencing results in bundling denials. We review infusion start/stop times and drug sequencing in every administration record before code assignment.
Unused drug from single-use vials is separately billable with modifier JW where payer rules allow. Most practices systematically miss JW billing — losing significant annual revenue on expensive drugs. We identify every eligible JW opportunity, document vial size vs. dose administered, and bill wastage on every qualifying claim.
Off-label chemotherapy use requires compendia support (NCCN, Micromedex, Clinical Pharmacology) cited in the prior authorization request. Without the correct compendia citation, the authorization and claim are denied for medical necessity. We submit complete oncology authorization packages with NCCN-cited indications for every off-label drug request.
Oncology patient data includes highly sensitive diagnosis, genetic, and treatment information. We operate under a signed Business Associate Agreement (BAA), encrypted data transmission, role-based access controls, and audit trail maintenance — meeting all CMS and OCR HIPAA requirements for oncology billing data handling.
Radiation therapy billing requires planning CPT codes (77261–77263), simulation (77280–77295), treatment delivery (77401–77432), and weekly management (77427). Each phase has distinct documentation requirements. We manage the complete radiation oncology billing cycle from treatment planning through final delivery and physician management.
Revenue Control Framework
End-to-end HIPAA-compliant oncology billing infrastructure — from drug procurement J-code to buy-and-bill reimbursement, with zero tolerance for J-code errors on high-cost drug claims.
Submit complete oncology authorization packages with diagnosis staging, NCCN compendia citations for off-label drugs, and treatment protocol documentation
Match J-code to drug administered, calculate units from dose administered (not ordered), and identify JW drug wastage opportunities before claim submission
Review administration records for drug sequence, start/stop times, and concurrent vs. sequential infusion — applying CPT 96413/96415/96417/96409/96411 correctly
Bill hydration infusions, antiemetics, growth factor injections, and port access separately — each has its own CPT/HCPCS code alongside chemotherapy
Encrypted electronic claim submission under BAA — all oncology patient data handled under CMS and OCR HIPAA standards with full audit trail
Compare every payment against ASP+6% rates, identify underpayments, and manage appeals with NCCN citation support for denied off-label claims
Operational Transformation
Why Medbilling RCM
Our oncology billing team understands J-code precision, chemotherapy sequencing rules, buy-and-bill reimbursement mechanics, drug wastage capture, NCCN compendia requirements for off-label authorization, and the HIPAA compliance standards that protect your oncology patient data.
Drug-matched HCPCS J-codes, dose-based unit calculation, and JW wastage capture on every chemotherapy claim — zero J-code errors on high-cost drugs.
CPT 96413/96415/96417 correctly sequenced per administration record — initial, sequential, and concurrent infusion rules applied on every encounter.
Every eligible single-use vial wastage identified and billed with modifier JW — recovering annual revenue most practices systematically miss.
Complete authorization packages with NCCN compendia citations for all off-label drug requests — preventing authorization denials for off-protocol chemotherapy.
Encrypted data handling, BAA executed before any data sharing, audit trails maintained — CMS and OCR-compliant oncology billing at every step.
Every specialist holds AAPC certification with oncology-specific training. CPT, ICD-10, and HCPCS J-code guidelines applied on every claim.
Full radiation oncology cycle: treatment planning (77261-77263), simulation, delivery, and weekly physician management (77427).
Every Medicare buy-and-bill payment compared against current ASP rates — underpayments identified and appealed with drug pricing documentation.
Common Questions
Direct answers about J-code accuracy, buy-and-bill, infusion sequencing, prior authorization, and HIPAA compliance. View all specialties we serve.
Every chemotherapy claim requires the exact HCPCS J-code matched to the drug name, dose, and administration route documented in the clinical record. J-code errors on high-cost oncology drugs can mean denials of $10,000–$150,000 per claim. We verify J-code selection against the drug administered, calculate units based on the dose administered (not the dose ordered), and apply modifier JW for drug wastage from single-use vials where payer rules allow.
Under the buy-and-bill model, oncology practices purchase chemotherapy drugs and seek reimbursement from payers after administration. Medicare reimburses at Average Sales Price (ASP) plus 6% for Part B drugs. Accurate J-code selection, correct unit calculation, timely claim submission, and effective denial management are critical — a denied claim for a $18,000-per-dose drug creates significant cash flow risk. We manage the complete buy-and-bill cycle from J-code to payment.
Chemotherapy infusion coding is sequence-dependent. The initial drug infusion is billed under CPT 96413 (first hour). Each additional hour of the same drug uses 96415. A second chemotherapy drug administered sequentially uses 96417. Concurrent infusions (two drugs running simultaneously) are coded differently from sequential infusions. We review infusion records, document start/stop times, and apply the correct initial/sequential/concurrent infusion hierarchy on every chemotherapy encounter.
Oncology prior authorizations require diagnosis codes, staging information, treatment protocol documentation, NCCN guideline citations for off-label drug use, and in many cases pathology reports and genomic testing results. We manage the complete oncology authorization workflow — submission, tracking, peer-to-peer coordination, and appeals — for all chemotherapy drugs, biologics, immunotherapy agents, and targeted therapy medications.
Yes. All our oncology billing services operate under strict HIPAA compliance protocols including encrypted data transmission, secure EHR integration, Business Associate Agreement (BAA) execution before any data sharing, role-based access controls, and audit trail maintenance. Our team undergoes annual HIPAA training and we conduct regular compliance audits to ensure patient data protection meets all CMS and OCR requirements.
Revenue Assessment
Schedule a free oncology billing assessment and discover how J-code accuracy, drug wastage capture, infusion sequencing compliance, and NCCN off-label authorization can significantly improve your practice collections.
